 LEXINGTON, Mass., March 23, 2021 PRNewswire -- Pulmatrix, Inc. NASDAQ: PULM, a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSETM technology, today reports its Q4 and full year 2020 financial results and provides a business update. 